|
Delayed
BME
07:03:59 2026-11-02 EST
|
5-day change | 1st Jan Change | ||
| 62.90 EUR | +0.56% |
|
+2.44% | -0.94% |
| 10-05 | Spanish stocks - Factors to watch on Oct 5 | RE |
| 07-23 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 |
Company Valuation: Laboratorios Farmaceuticos Rovi, S.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 4,138 | 1,925 | 3,213 | 3,220 | 3,248 | 3,199 | - | - |
| Change | - | -53.49% | 66.93% | 0.22% | 0.87% | -1.51% | - | - |
| Enterprise Value (EV) 1 | 4,112 | 1,872 | 3,251 | 3,305 | 3,272 | 3,195 | 3,156 | 3,036 |
| Change | - | -54.48% | 73.7% | 1.65% | -1% | -2.36% | -1.2% | -3.79% |
| P/E | 26.7x | 9.67x | 18.8x | 23.6x | 23.1x | 19.8x | 18.9x | 15.9x |
| PBR | 8.59x | 3.71x | 5.94x | 5.63x | 4.89x | 4.11x | 3.57x | 3.1x |
| PEG | - | 0.3x | -1.3x | -1.4x | 7.71x | 1.3x | 3.98x | 0.8x |
| Capitalization / Revenue | 6.38x | 2.35x | 3.87x | 4.22x | 4.37x | 4.1x | 3.57x | 3.3x |
| EV / Revenue | 6.34x | 2.29x | 3.92x | 4.33x | 4.4x | 4.09x | 3.52x | 3.13x |
| EV / EBITDA | 20.3x | 6.72x | 13.3x | 15.9x | 15.1x | 15.5x | 12.4x | 10.1x |
| EV / EBIT | 22.7x | 7.32x | 14.8x | 18.4x | 17.6x | 18.5x | 14.4x | 11.6x |
| EV / FCF | 37.9x | 10.1x | 54.3x | 43.5x | 27.4x | 30.7x | 26.1x | 18.7x |
| FCF Yield | 2.64% | 9.95% | 1.84% | 2.3% | 3.65% | 3.26% | 3.83% | 5.35% |
| Dividend per Share 2 | 0.9556 | 1.294 | 1.104 | 0.9351 | 0.9594 | 0.9504 | 1.18 | 1.249 |
| Rate of return | 1.29% | 3.59% | 1.83% | 1.49% | 1.51% | 1.52% | 1.89% | 2% |
| EPS 2 | 2.76 | 3.73 | 3.2 | 2.67 | 2.75 | 3.159 | 3.309 | 3.944 |
| Distribution rate | 34.6% | 34.7% | 34.5% | 35% | 34.9% | 30.1% | 35.7% | 31.7% |
| Net sales 1 | 648.7 | 817.7 | 829.5 | 763.7 | 743.5 | 780.3 | 896 | 969 |
| EBITDA 1 | 202.9 | 278.7 | 244.5 | 207.4 | 216.2 | 205.9 | 255.1 | 299.8 |
| EBIT 1 | 181.5 | 255.8 | 220.1 | 179.4 | 185.8 | 172.7 | 219 | 262.3 |
| Net income 1 | 153.1 | 199.7 | 170.3 | 136.9 | 140.4 | 146.3 | 170 | 201.5 |
| Net Debt 1 | -25.87 | -52.78 | 38.6 | 85.1 | 23.84 | -4.428 | -42.91 | -162.6 |
| Reference price 2 | 73.80 | 36.06 | 60.20 | 62.95 | 63.50 | 62.55 | 62.55 | 62.55 |
| Nbr of stocks (in thousands) | 56,069 | 53,375 | 53,370 | 51,149 | 51,149 | 51,143 | - | - |
| Announcement Date | 2/23/22 | 2/21/23 | 2/27/24 | 2/25/25 | 2/24/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.8x | 4.09x | 15.52x | 1.52% | 3.57B | |
| 41.42x | 14.01x | 31.06x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 36.71x | 8.6x | 17.71x | 2.35% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 97.38x | 6.07x | 25.8x | 2.28% | 369B | |
| 23.19x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.47x | 4.89x | 13.87x | 1.77% | 290B | |
| 29.55x | 7.53x | 13.48x | 2.16% | 252B | |
| -40.86x | 7.45x | 46.76x | 1.94% | 212B | |
| Average | 29.34x | 7.06x | 21.06x | 1.96% | 426.55B | |
| Weighted average by Cap. | 36.39x | 8.82x | 22.81x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ROVI Stock
- Valuation Laboratorios Farmaceuticos Rovi, S.A.
Select your edition
All financial news and data tailored to specific country editions
